Hydroxyurea and Fertility in Sickle Cell Disease
- This article reports on a study presented at the ASH Annual Meeting regarding the use of hydroxyurea during pregnancy in women with sickle cell disease.
- * Background: There's been concern that hydroxyurea, while beneficial for managing sickle cell disease, might cause end-organ damage, potentially affecting the uterus and ovaries.
- In essence, the article suggests that continuing hydroxyurea during the first trimester may be safer than previously thought, and stopping it can lead to increased complications in some...
Summary of the Article: Hydroxyurea Use During Pregnancy in Sickle cell Disease
This article reports on a study presented at the ASH Annual Meeting regarding the use of hydroxyurea during pregnancy in women with sickle cell disease. Here’s a breakdown of the key takeaways:
* Background: There’s been concern that hydroxyurea, while beneficial for managing sickle cell disease, might cause end-organ damage, potentially affecting the uterus and ovaries. Historically, many doctors advised patients to stop taking hydroxyurea before attempting to conceive.
* Study Findings: A real-world study showed generally good outcomes for women who continued hydroxyurea during the first trimester. No specific issues in newborns were directly linked to hydroxyurea exposure.
* Clinical Implications: The author (Dr. Ali) notes a concerning trend: patients who stopped hydroxyurea before pregnancy are experiencing more complications, including needing exchange transfusions and developing new antibodies.
* Shared Decision-Making: The data supports a more nuanced approach to the decision of whether to continue or discontinue hydroxyurea before pregnancy. While not proving complete safety, the real-world data is valuable for informed discussions with patients.
* Importance of the Study: The study was selected for a plenary session presentation, highlighting its significance.
In essence, the article suggests that continuing hydroxyurea during the first trimester may be safer than previously thought, and stopping it can lead to increased complications in some patients. It emphasizes the need for individualized risk-benefit assessments and shared decision-making between doctors and their patients.
Disclosures:
* Dr. Ali: No relevant financial disclosures.
* Habibi (lead researcher): Relationships with Novo Nordisk, Pfizer, and theravia. (full disclosures for all authors are available in the study itself).
* Source: Habibi A, et al.Presented at: ASH Annual Meeting and Exposition; Dec. 6-9,2025; Orlando.